119 related articles for article (PubMed ID: 38642580)
1. Impact of systemic treatments for advanced thyroid cancer on the adrenal cortex.
Colombo C; Ceruti D; Succi M; De Leo S; Trevisan M; Moneta C; Fugazzola L
Eur Thyroid J; 2024 Jun; 13(3):. PubMed ID: 38642580
[TBL] [Abstract][Full Text] [Related]
2. Primary Adrenal Insufficiency During Lenvatinib or Vandetanib and Improvement of Fatigue After Cortisone Acetate Therapy.
Colombo C; De Leo S; Di Stefano M; Vannucchi G; Persani L; Fugazzola L
J Clin Endocrinol Metab; 2019 Mar; 104(3):779-784. PubMed ID: 30383218
[TBL] [Abstract][Full Text] [Related]
3. Cortisol Deficiency in Lenvatinib Treatment of Thyroid Cancer: An Underestimated Common Adverse Event.
Monti S; Presciuttini F; Deiana MG; Motta C; Mori F; Renzelli V; Stigliano A; Toscano V; Pugliese G; Poggi M
Thyroid; 2022 Jan; 32(1):46-53. PubMed ID: 34663079
[No Abstract] [Full Text] [Related]
4. Salvage Lenvatinib Therapy in Metastatic Anaplastic Thyroid Cancer.
Iñiguez-Ariza NM; Ryder MM; Hilger CR; Bible KC
Thyroid; 2017 Jul; 27(7):923-927. PubMed ID: 28471306
[TBL] [Abstract][Full Text] [Related]
5. Comparative efficacy and safety of tyrosine kinase inhibitors for thyroid cancer: a systematic review and meta-analysis.
Oba T; Chino T; Soma A; Shimizu T; Ono M; Ito T; Kanai T; Maeno K; Ito KI
Endocr J; 2020 Dec; 67(12):1215-1226. PubMed ID: 32814730
[TBL] [Abstract][Full Text] [Related]
6. The effect of growth hormone replacement therapy on adrenal androgen secretion in adult onset hypopituitarism.
Isidori AM; Kaltsas GA; Perry L; Burrin JM; Besser GM; Monson JP
Clin Endocrinol (Oxf); 2003 May; 58(5):601-11. PubMed ID: 12699442
[TBL] [Abstract][Full Text] [Related]
7. A Phase II study of the safety and efficacy of lenvatinib in patients with advanced thyroid cancer.
Takahashi S; Kiyota N; Yamazaki T; Chayahara N; Nakano K; Inagaki L; Toda K; Enokida T; Minami H; Imamura Y; Fukuda N; Sasaki T; Suzuki T; Ikezawa H; Dutcus CE; Tahara M
Future Oncol; 2019 Mar; 15(7):717-726. PubMed ID: 30638399
[TBL] [Abstract][Full Text] [Related]
8. Safety and Quality-of-Life Data from an Italian Expanded Access Program of Lenvatinib for Treatment of Thyroid Cancer.
Giani C; Valerio L; Bongiovanni A; Durante C; Grani G; Ibrahim T; Mariotti S; Massa M; Pani F; Pellegriti G; Porcelli T; Salvatore D; Tavarelli M; Torlontano M; Locati L; Molinaro E; Elisei R
Thyroid; 2021 Feb; 31(2):224-232. PubMed ID: 32907501
[No Abstract] [Full Text] [Related]
9. Incidence and timing of common adverse events in Lenvatinib-treated patients from the SELECT trial and their association with survival outcomes.
Haddad RI; Schlumberger M; Wirth LJ; Sherman EJ; Shah MH; Robinson B; Dutcus CE; Teng A; Gianoukakis AG; Sherman SI
Endocrine; 2017 Apr; 56(1):121-128. PubMed ID: 28155175
[TBL] [Abstract][Full Text] [Related]
10. Lenvatinib in Advanced Radioiodine-refractory Thyroid Cancer: A Snapshot of Real-life Clinical Practice.
Nervo A; Gallo M; Samà MT; Felicetti F; Alfano M; Migliore E; Marchisio F; Berardelli R; Arvat E; Piovesan A
Anticancer Res; 2018 Mar; 38(3):1643-1649. PubMed ID: 29491097
[TBL] [Abstract][Full Text] [Related]
11. Testosterone administration increases adrenal response to adrenocorticotrophin.
Polderman KH; Gooren LJ; van der Veen EA
Clin Endocrinol (Oxf); 1994 May; 40(5):595-601. PubMed ID: 8013140
[TBL] [Abstract][Full Text] [Related]
12. Rare complications of multikinase inhibitor treatment.
Pitoia F; Schmidt A; Bueno F; Abelleira E; Jerkovich F
Arch Endocrinol Metab; 2018; 62(6):636-640. PubMed ID: 30624504
[TBL] [Abstract][Full Text] [Related]
13. Adrenal insufficiency in thyroid cancer patients treated with tyrosine kinase inhibitors and detected by ACTH stimulation test.
Valerio L; Giani C; Matrone A; Pontillo-Contillo B; Minaldi E; Agate L; Molinaro E; Elisei R
J Endocrinol Invest; 2023 Aug; 46(8):1663-1671. PubMed ID: 36809657
[TBL] [Abstract][Full Text] [Related]
14. Novel therapies for thyroid cancer.
Krajewska J; Jarzab B
Expert Opin Pharmacother; 2014 Dec; 15(18):2641-52. PubMed ID: 25318585
[TBL] [Abstract][Full Text] [Related]
15. Lenvatinib: Role in thyroid cancer and other solid tumors.
Cabanillas ME; Habra MA
Cancer Treat Rev; 2016 Jan; 42():47-55. PubMed ID: 26678514
[TBL] [Abstract][Full Text] [Related]
16. Real-world efficacy and safety of lenvatinib: data from a compassionate use in the treatment of radioactive iodine-refractory differentiated thyroid cancer patients in Italy.
Locati LD; Piovesan A; Durante C; Bregni M; Castagna MG; Zovato S; Giusti M; Ibrahim T; Puxeddu E; Fedele G; Pellegriti G; Rinaldi G; Giuffrida D; Verderame F; Bertolini F; Bergamini C; Nervo A; Grani G; Rizzati S; Morelli S; Puliafito I; Elisei R
Eur J Cancer; 2019 Sep; 118():35-40. PubMed ID: 31299580
[TBL] [Abstract][Full Text] [Related]
17. [Drug approval: Selpercatinib and pralsetinib - RET-altered thyroid cancer].
Courtier B; Hadoux J
Bull Cancer; 2021 Nov; 108(11):989-991. PubMed ID: 34598787
[No Abstract] [Full Text] [Related]
18. Defining Radioiodine-Refractory Differentiated Thyroid Cancer: Efficacy and Safety of Lenvatinib by Radioiodine-Refractory Criteria in the SELECT Trial.
Kiyota N; Robinson B; Shah M; Hoff AO; Taylor MH; Li D; Dutcus CE; Lee EK; Kim SB; Tahara M
Thyroid; 2017 Sep; 27(9):1135-1141. PubMed ID: 28665259
[TBL] [Abstract][Full Text] [Related]
19. Transitory hypoadrenalism due to long-term treatment with antiovulatory compounds.
Leiba S; Kaufman H; Winkelsberg G; Bahary C
Isr J Med Sci; 1979 May; 15(5):434-7. PubMed ID: 221439
[TBL] [Abstract][Full Text] [Related]
20. Vandetanib for the treatment of advanced medullary thyroid cancer outside a clinical trial: results from a French cohort.
Chougnet CN; Borget I; Leboulleux S; de la Fouchardiere C; Bonichon F; Criniere L; Niccoli P; Bardet S; Schneegans O; Zanetta S; Schvartz C; Drui D; Chauffert B; Rohmer V; Schlumberger M
Thyroid; 2015 Apr; 25(4):386-91. PubMed ID: 25627619
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]